These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 19925284

  • 1. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.
    Guney I, Selcuk NY, Altintepe L, Atalay H, Başarali MK, Büyükbaş S.
    Ren Fail; 2009; 31(9):779-84. PubMed ID: 19925284
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.
    Sengul E, Sahin T, Sevin E, Yilmaz A.
    Ren Fail; 2009; 31(10):928-32. PubMed ID: 20030528
    [Abstract] [Full Text] [Related]

  • 6. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY, Bae EH, Ma SK, Kim SW.
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ.
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
    Ustundag A, Tugrul A, Ustundag S, Sut N, Demirkan B.
    Ren Fail; 2008 Mar; 30(10):982-91. PubMed ID: 19016150
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 17. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S, Takeuchi K, Mori T, Nako K, Ito S.
    Clin Exp Pharmacol Physiol; 2006 Apr; 33(5-6):477-9. PubMed ID: 16700881
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):264-71. PubMed ID: 18582458
    [Abstract] [Full Text] [Related]

  • 20. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
    Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 28; 5(3):146-51. PubMed ID: 15526251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.